PDCD1 and bladder transitional cell carcinoma: Several immune checkpoint inhibitors targeting programmed cell death protein 1 (PD1) and its ligands PDL1 and cytotoxic T lymphocyte-associated protein 4 (CTLA4) have been approved for BLCA.